A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 532 participants.

Also called NCT02906917

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 532 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02906917
  • EudraCT 2015-004768-12
Other papers using this trial's data
  • Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus Diabetes research and clinical practice, 2019-01 DOI, PubMed 30448451

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Algeria, Czechia, India, Russia, Serbia, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02906917. Randomized; no masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2017-08-31 (actual). Results posted on 2018-09-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin degludec/insulin aspart
Intervention (Drug)
Insulin glargine
Intervention (Drug)
Insulin aspart
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02906917
Content hash
9047bfbaaf06f3c48c5d71ba0f09e2597e9f0039b4eb2caf4f921e3c1b7fe015